The Disappearing Farmer
Cannabis reform was meant to restore justice. Farmers who carried the plant through prohibition were promised recognition. Communities were told they would share in the new markets. Patients were told safe, affordable access was coming.
Instead, the farmer is disappearing.
The fields remain, but the rules now belong to another world. Compliance has replaced cultivation. Capital has replaced knowledge.
Hands that once nurtured the plant are being told they are no longer clean enough to touch it.
From GACP to GMP: When Farming Becomes Pharma
In July 2025, the European Medicines Agency quietly published a revision of its Good Agricultural and Collection Practice (GACP) guideline. On paper it looks like quality control. In practice, it folds farming into pharma.
The revision demands digital traceability, validated lab infrastructure, supplier contracts referencing GACP, and audit trails across cultivation and storage. It declares that those who “embrace” the standard will thrive, while those who don’t will “fall away.”
This isn’t guidance, it’s a filter.
- In Germany, only a handful of corporates can meet the EU-GMP aligned rules, leaving independent growers shut out. This concentration of supply shows how quickly “medical access” becomes corporate monopoly.
- In Portugal, dozens of export facilities ship GMP-certified flower to Germany while domestic patients struggle to access any. Here, the export machine runs smoothly while local access remains deliberately broken.
- In New Zealand, GMP requirements delayed patient access for years, while corporates secured export deals to Australia. The rules were written to privilege exports over domestic relief.
- In Australia, small growers are forced through TGA GMP audits that community-scale operations cannot survive. Only corporates with deep capital can endure the process.
- In the US, DEA-licensed research grows move into pharma pipelines, while licensed state farmers are barred from even crossing state lines. Once again, rules that claim to ensure safety instead guarantee exclusion.
Different continents, same outcome: farming is no longer judged on quality or heritage, but on its ability to mimic pharmaceutical compliance.
What was once agricultural guidance has been rewritten as a pharmaceutical gatekeeping system. Farming itself has been redefined as pre-GMP manufacturing.
This is what we call being folded into pharma.
Big Pharma’s Playbook
If GACP is the gate, pharma already holds the keys. The Leafwire investigation outlined the strategy:
- Patents and IP Fortresses: sweeping claims on cannabinoids, delivery methods, and formulations.
- Acquisitions: Jazz’s $7.2B takeover of GW Pharma, Pfizer’s purchase of Arena Pharma — securing pipelines and orphan drug markets.
- DEA and Research Licences: U.S. firms monopolising “legitimate” research through federally aligned suppliers.
- Synthetics: dronabinol, nabiximols, and other analogues bypassing agriculture altogether.
- Lobbying and Finance: pharma PACs shaping rescheduling, SAFE Banking, and FDA pathways.
When pharma frames the rules, cannabis is rewritten as chemistry, not culture.
Taken together, these moves reveal a playbook: acquire the assets, rewrite the definitions, then patent the future.
California shows the consequences on the ground. Humboldt’s legacy farmers — once the backbone of supply — have been buried under METRC compliance, taxes, and corporate price wars. Legal sales amount to just over a million pounds a year, while the illicit market moves more than ten times that.
Pharma no longer fights cannabis. It is preparing to own it.
Reschedule vs Deschedule: Framing the Future
The U.S. rescheduling debate shows what is really at stake.
Rescheduling to Schedule III is not legalisation. State programs remain federally illegal. Migrants can still be deported for possession. Small businesses remain vulnerable.
It does repeal 280E tax penalties, but the relief mainly benefits large corporates who already dominate.
More dangerously, it hands control to the FDA. Under Schedule III, cannabis products would require pharma-style approvals. That means clinical trials, lab dossiers, and regulatory submissions that only corporates can afford. Equity programmes will not survive this framework.
As High Times warned, Schedule III may be worse than standing still. It locks cannabis inside pharma’s paperwork.
Descheduling is the real alternative. Removing cannabis from narcotics law would allow agricultural regulation and consumer access. Cannabis would be treated like hops, grapes, or tobacco — crops with culture, not molecules with patents.
But the global system moves the other way.
The 2020 UN Commission on Narcotic Drugs only downgraded cannabis from Schedule IV to Schedule I, leaving it trapped in the Single Convention. Donors and regulators now cite this to justify pharma alignment.
The pertinent truth: the U.S. does not need a Security Council veto at the CND. Its money and markets are the veto. Washington funds the UN drug-control system, controls the largest consumer market, and sets the regulatory models others mirror.
When the FDA defines cannabis as Schedule III pharma, Bogotá, Lisbon, Athens, and Berlin all fall in line.
The U.S. circus over rescheduling does not just shape its own market.
It holds the global cannabis trade to ransom.
Donor Politics as Reinforcement
Donors are not neutral. They are amplifiers of exclusion.
- In Europe, development banks like the EIB and KfW finance cannabis projects in Portugal, Denmark, and Greece — but only if they are export-focused, GMP-aligned, and corporate-backed. Community farmers cannot qualify.
- In the UK, the Novel Foods regime functioned like donor conditionality in disguise. Only companies with millions to spend on toxicology dossiers could stay on the approved list. Hundreds of small CBD startups were erased overnight.
- In Canada, Health Canada’s cost-recovery model mimics donor politics at home. High fees and slow licensing effectively became a financing filter: corporates with patient capital survived, small farmers folded.
Different settings, same story: donor-aligned finance rewards corporates, while everyone else is squeezed out.
These mechanisms are then exported to the Global South. African DFIs borrow the logic of European financiers. Latin American governments adopt the frameworks set in Brussels. Donor rules in developed economies become donor barriers everywhere else.
Capital flows uphill, never down.
The Marginalisation of Patients and Farmers
Patients and farmers were promised inclusion. Both were sidelined.
- In Greece, patients were told reform would bring access. Instead, domestic flower is exported to Germany while locals face pharma-priced imports. A promise of access became a pipeline out.
- In Portugal, dozens of export facilities ship to Europe, yet local patients still rely on grey channels. The country is a hub for GMP exports, but its own citizens are left unserved.
- In Spain, community cannabis clubs remain criminalised even as corporates prepare to export. What began as a grassroots model of access is now treated as a threat to corporate interests.
- In the UK, patients pay thousands for prescriptions through a handful of corporate clinics while illicit markets remain the real source of access.
Legalisation has not delivered relief — it has delivered gatekeepers.
Different countries, same pattern: exports are prioritised, patients are marginalised, and the promise of access is hollowed out.
Farmers face the same exclusion.
- In Canada, craft cultivators drowned under excise taxes and distributor markups. While corporate oversupply sat rotting in warehouses, independents simply could not compete.
- In the US, Humboldt’s legacy growers collapsed under the weight of compliance, while equity licensees in cities found the costs of entry insurmountable. What was billed as opportunity became exclusion by design.
- In New Zealand, small farmers who expected to supply patients were sidelined as corporates geared production for export. Local promise gave way to global priorities.
Different geographies, same outcome: the system is designed to erase farmers while rewarding corporates who can play the compliance game.
The insult runs deeper than economics. Patients are told their senses are irrelevant — legal equals safe, illicit equals dangerous. Farmers are told their knowledge is invalid — heritage methods equal risk, pharma paperwork equals quality.
Generational wisdom is being erased. And in its place, a system of paternalism tells patients and farmers they no longer know their own medicine.
From Plant to Patent
Alcohol was regulated. Tobacco was taxed. Cannabis is being rewritten.
Not as agriculture. Not as culture. But as pharmaceuticals.
The transformation is visible:
- GW Pharma turned greenhouse flower into Epidiolex — an FDA-approved drug, patented and guarded from competition. It set the template for folding cannabis into pharma.
- Jazz Pharma is expanding that pipeline into synthetics, pushing further away from plant-based medicine and deeper into lab-derived monopolies.
- Tilray and Canopy Growth are pivoting away from cultivation into IP portfolios and pharma contracts. For them, the future is not farming — it’s intellectual property.
- Pfizer, through its acquisition of Arena, is positioning for a future where cannabinoids are patented molecules, not community crops. When pharma frames the rules, cannabis is rewritten as chemistry, not culture.
Different companies, same destination: the plant is no longer treated as a plant. It is being recast as a pharmaceutical input.
What this means is profound. Molecules become property. Variability becomes defect. Traditional methods become contamination.
Donors and regulators reinforce the shift. GACP collapses farming into pre-GMP. Funding only flows to pharma-style builds. Compliance rules define the crop as a drug before it ever reaches a patient.
The monopoly is not just over markets. It is over definitions.
Farmers become subcontractors, stripped of agency. Patients consume remediated flower sold in blister packs. Communities lose the right to define their own medicine.
The tragedy is not only that cannabis has been captured. It is that its essence — as plant, culture, and medicine of the people — is being erased and rewritten as property of the few.
Who Wins, Who Loses
Winners:
- Pharma — patents, acquisitions, synthetics, FDA alignment.
- Regulators — expanded budgets, donor legitimacy.
- Donors — applause for “supporting development” without delivering it.
Losers:
- Farmers — excluded by design.
- Patients — trapped in dependency.
- Communities — promised inclusion, delivered exclusion.
Closing Call
Cannabis reform was meant to deliver renewal. Instead, it has delivered capture.
Pharma does not just want a share of the market. It wants to define the plant itself. Donors do not just want to support development. They want to police it. Regulators do not just want safety. They want survival.
The result is a future already mapped: pharma vs farmer.
Pharma brings patents, GMP, donor theatre, exclusion.
Farmers bring culture, continuity, and community.
Unless resisted, this will not be a debate. It will be a surrender.
The question is not whether cannabis is legal.
The question is: who is it legal for?
#
